advanced-stem-cell-2018-scientifictracks

7 / 12

Advanced Stem Cell 2018 Journal of Stem Cell Biology and Transplantation
ISSN: 2575-7725 Page 29
December 03-04, 2018
Valencia, Spain
15th Edition of EuroSciCon Conference on
Advanced Stem Cell &
Regenerative Medicine
Duchenne muscular dystrophy (DMD) is an inherited disorder
caused by mutation in gene that prevents the translation
of dystrophin protein, which leads to massive skeletal muscle
wasting. Any form of muscular dystrophy is considered as an
incurable disease yet there are occupational treatments assisting
patients with locomotion strengthening and to further extend
the lifespan. Thus, emerging treatment strategy is warranted
to improve patients’ conditions from DMD. In the present study,
we have evaluated the therapeutic outcome of human umbilical
cord derived mesenchymal stem cell (hUC-MSC) in patients
with DMD. In light of that, we have produced therapeutically
safe (chromosomal stability, stable immunophenotyping and
mesodermal lineage differentiation ability) hUC-MSCs in our
GMP compliance laboratory. Patients (24 and 27 years old) were
administrated- intravenous (50X106) + intramuscular (50X106)
one single dose of hUC-MSC and followed up for 12 months.
Therapeutic efficacy was measured as based on the level of
creatinine phosphokinase (CK) in plasma. Both patients were
highly responsive to hUC- MSC and the CK level was significantly
dropped from 3rd month of post transplantation. After 12 months
of post transplantation the CK level was slightly increased in both
patients as compared to 6th month. However, the level of CK level
was still significantly lower than basal level. In conclusion, one
single dose of hUC-MSCs treatment may not be sufficient to give
better clinical outcome and also these results suggested that
multi-dose of hUC-MSCs may give long term beneficial effects in
patients with DMD.
Biography
Ke Shyang See Kris has a keen interest in the research and therapeutics of
neuro-trauma, neurodegenerative diseases and genomic medicine. Kris has
worked for variousmedical institutions both in the public and private sectors
in the past. In 2011, he won the “People’s Choice Award” in neurosurgery
conferred by Hospital Sultanah Bahiyah, Kedah, Malaysia. In 2016, he was
awarded “Most Impactful Entrepreneur Award”. In 2017, he was awarded
KWYP “Dr. Sun Yat-Sen Best Enterprise Award”, Malaysia “Top 100 Most In-
fluential Young Entrepreneur” award and during an international symposium
organized by Korean College of Radiology, he was awarded the Grand Prix
award for Best Photo in people category. In 2017, as Chief Clinical Scien-
tist of Osel Diagnostics Lab, they were awarded “Best Innovative Screening
– Blood Based Approach” for innovative genetic screening by Asian Halal
Brands Awards making it the first lab in Asean to be conferred the presti-
gious award. In 2018, Dr. Kris is the scholarship recipient for the prestigious
Harvard Medical School South East Asia Medical Leaders program. In the
same year, he was awarded The Excellence Achievement Entrepreneurs
Award – International Entrepreneurs Business Conference 2018. He is cur-
rently serving as the Medical Director of Osel Group, Chief Clinical Scientist
of Osel Diagnostics, Clinical Scientist with Auto Stem Laboratories, Visiting
Consultant and Research Associate with Niscell Laboratories, Visiting Re-
search Associate with Hygieia Laboratories. In 2017, Dr. Kris was appointed
a faculty member of The Frontier Medicine Institute – advocating health-
care innovations and building bridges between education and healthcare,
brought about by the Fourth Industrial Revolution. The same year, He was
appointed a co-supervisor research project in University Science Malaysia,
Penang, for research interests in the “Biological Activities in Durian”. Dr. Kris
is also the editor-in-chief for The Frontier Medical Journal, an open access
peer reviewed journal. Currently he is the founding member and advisor for
Wings of Love – a community based not- for-profit mobile clinic, Penang,
the medical adviser for Serdang Badminton Club and Penang Badminton
Club. He is also the adviser for Kiddo Science JB, where he shares his in-
sights about early childhood education. He is serving as medical advisor for
Kopan Free Clinic in Kathmandu, Nepal. Previously, He was serving as the
Medical Adviser for Yayasan Medical Foundation. Dr. Kris is instrumental
in advocating and setting up “The Tan Hong Mui Scholarship”, where he is
appointed as one of the panel of judges for selecting deserving students to
pursue creative arts industry. Dr. Kris See is immensely passionate about
empowering the youth in education and medicine arena. He is frequently
invited to give keynote speeches both domestically and internationally. In
his free time, he contributes to various charitable organizations both within
Malaysia and overseas.
Therapeutic consequence of allogeneic
mesenchymal stem cell for Duchenne muscular
dystrophy: case study
Ke Shyang See Kris
Osel Group, Malaysia; Osel Diagnostics Sdn Bhd (Lab), Malaysia; Osel Clinic, Malaysia
Ke Shyang See Kris, J Stem Cell Biol Transplant 2018, Volume 2
DOI: 10.21767/2575-7725-C1-002